Tags

Type your tag names separated by a space and hit enter

Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.
J Spinal Cord Med 2002; 25(2):100-5JS

Abstract

BACKGROUND

Neuropathic pain is a common complaint after traumatic spinal cord injury (SCI). Gabapentin, a synthetic structural analogue of GABA, has been shown to have beneficial effects in the treatment of neuropathic pain in other diagnostic groups; however, no standardized clinical trial has been performed to evaluate its efficacy after SCI.

DESIGN

A 10-week, prospective, randomized, double-blind, crossover, and placebo-controlled clinical trial.

OBJECTIVE

To determine the efficacy of gabapentin in the treatment of SCI-related neuropathic pain.

METHODS

Seven subjects with neuropathic pain, who were more than 30 days post-SCI, completed the study. Two groups received a 4-week course of gabapentin and placebo in a randomized crossover design with a 2-week washout period. The Neuropathic Pain Scale was used to record daily pain levels. Data were analyzed using the Wilcoxon signed rank test.

RESULTS

Gabapentin has some beneficial effects on certain types of neuropathic pain. There was a significant decrease of "unpleasant feeling" and a trend toward a decrease in both the "pain intensity" and "burning sensation" at the fourth week of gabapentin treatment compared with those on the placebo. No significant difference was found among other pain descriptors during the gabapentin and placebo treatment, although this may have been limited by the small sample size and low maximum dosage of gabapentin.

CONCLUSIONS

Gabapentin reduces certain types of neuropathic pain in the SCI population. Future studies with larger sample sizes, higher dosages, and quicker titration will help further determine the efficacy of gabapentin in the treatment of SCI-related neuropathic pain.

Authors+Show Affiliations

UMDNJ-New Jersey Medical School, Newark, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12137213

Citation

Tai, Qing, et al. "Gabapentin in the Treatment of Neuropathic Pain After Spinal Cord Injury: a Prospective, Randomized, Double-blind, Crossover Trial." The Journal of Spinal Cord Medicine, vol. 25, no. 2, 2002, pp. 100-5.
Tai Q, Kirshblum S, Chen B, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25(2):100-5.
Tai, Q., Kirshblum, S., Chen, B., Millis, S., Johnston, M., & DeLisa, J. A. (2002). Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. The Journal of Spinal Cord Medicine, 25(2), pp. 100-5.
Tai Q, et al. Gabapentin in the Treatment of Neuropathic Pain After Spinal Cord Injury: a Prospective, Randomized, Double-blind, Crossover Trial. J Spinal Cord Med. 2002;25(2):100-5. PubMed PMID: 12137213.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. AU - Tai,Qing, AU - Kirshblum,Steven, AU - Chen,Boqing, AU - Millis,Scott, AU - Johnston,Mark, AU - DeLisa,Joel A, PY - 2002/7/26/pubmed PY - 2003/1/15/medline PY - 2002/7/26/entrez SP - 100 EP - 5 JF - The journal of spinal cord medicine JO - J Spinal Cord Med VL - 25 IS - 2 N2 - BACKGROUND: Neuropathic pain is a common complaint after traumatic spinal cord injury (SCI). Gabapentin, a synthetic structural analogue of GABA, has been shown to have beneficial effects in the treatment of neuropathic pain in other diagnostic groups; however, no standardized clinical trial has been performed to evaluate its efficacy after SCI. DESIGN: A 10-week, prospective, randomized, double-blind, crossover, and placebo-controlled clinical trial. OBJECTIVE: To determine the efficacy of gabapentin in the treatment of SCI-related neuropathic pain. METHODS: Seven subjects with neuropathic pain, who were more than 30 days post-SCI, completed the study. Two groups received a 4-week course of gabapentin and placebo in a randomized crossover design with a 2-week washout period. The Neuropathic Pain Scale was used to record daily pain levels. Data were analyzed using the Wilcoxon signed rank test. RESULTS: Gabapentin has some beneficial effects on certain types of neuropathic pain. There was a significant decrease of "unpleasant feeling" and a trend toward a decrease in both the "pain intensity" and "burning sensation" at the fourth week of gabapentin treatment compared with those on the placebo. No significant difference was found among other pain descriptors during the gabapentin and placebo treatment, although this may have been limited by the small sample size and low maximum dosage of gabapentin. CONCLUSIONS: Gabapentin reduces certain types of neuropathic pain in the SCI population. Future studies with larger sample sizes, higher dosages, and quicker titration will help further determine the efficacy of gabapentin in the treatment of SCI-related neuropathic pain. SN - 1079-0268 UR - https://www.unboundmedicine.com/medline/citation/12137213/Gabapentin_in_the_treatment_of_neuropathic_pain_after_spinal_cord_injury:_a_prospective_randomized_double_blind_crossover_trial_ L2 - https://medlineplus.gov/spinalcordinjuries.html DB - PRIME DP - Unbound Medicine ER -